301239.SZ
普瑞眼科
SZSE · Q 卫生 · CN
CNY 35.29
+0.83%Year over year
Reported trailing growth
- Revenue
- +4.8%
- EBITDA
- —
- EBIT
- +267.0%
- EPS
- +80.1%
- Free cash flow
- +467.1%
- Operating cash flow
- +16.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +17.5%
- EBITDA
- +12.3%
- EBIT
- -22.8%
- Net income
- +40.2%
- EPS
- +39.7%
- Free cash flow
- +298.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026